Abstract:Damage to genetic material represents a persistent and ubiquitous threat to genomic stability. Once DNA damage is detected, a multifaceted signaling network is activated that halts the cell cycle, initiates repair, and in some instances induces apoptotic cell death. In this article, we will review DNA damage surveillance networks, which maintain the stability of our genome, and discuss the efforts underway to identify chemotherapeutic compounds targeting the core components of DNA double-strand breaks (DSB) response pathway. The majority of tumor cells have defects in maintaining genomic stability owing to the loss of an appropriate response to DNA damage. New anticancer agents are exploiting this vulnerability of cancer cells to enhance therapeutic indexes, with limited normal tissue toxicity. Recently inhibitors of the checkpoint kinases Chk1 and Chk2 have been shown to sensitize tumor cells to DNA damaging agents. In addition, the treatment of BRCA1or BRCA2-deficient tumor cells with poly(ADP-ribose) polymerase (PARP) inhibitors also leads to specific tumor killing. Due to the numerous roles of p53 in genomic stability and its defects in many human cancers, therapeutic agents that restore p53 activity in tumors are the subject of multiple clinical trials. In this article we highlight the proteins mentioned above and catalog several additional players in the DNA damage response pathway, including ATM, DNA-PK, and the MRN complex, which might be amenable to pharmacological interventions and lead to new approaches to sensitize cancer cells to radioand chemotherapy. The challenge is how to identify those patients most receptive to these treatments. (Clin Cancer Res 2009;15(20):6314–20)

Development and therapeutic potential of DNA-dependent protein kinase inhibitors

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)

DNA-Dependent Protein Kinase Catalytic Subunit (DNA-PKcs): Beyond the DNA Double-Strand Break Repair

DNA-PK as an Emerging Therapeutic Target in Cancer

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

DNA-PKcs: A Multi-Faceted Player in DNA Damage Response

Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy

Advancing cancer therapy: new frontiers in targeting DNA damage response

The multifaceted functions of DNA-PKcs: implications for the therapy of human diseases

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Secrets of DNA-PKcs beyond DNA repair

DNA damage response in breast cancer and its significant role in guiding novel precise therapies

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

Targeting DNA damage response deficiency in the treatment of breast cancer

Impact of Optimized Ku–DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response

Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of Malignancies